[Fatal familiar insomnia: clinical, neurophysiological and histopathological study of two cases]

T Ayuso Blanco1, J Urriza Mena, C Caballero Martínez

  • 1Servicio de Neurologia, Hospital de Navarra, Irunlarrea, Pamplona. tayusob@yahoo.es

Abstract

Insights

Fatal familial insomnia (FFI) is a rare prion disease. This study details two cases with a specific genetic mutation (D178N-129M), highlighting severe sleep disruption and rapid progression.

Area of Science:

  • Neuroscience
  • Genetics
  • Sleep Medicine

Background:

  • Family prion diseases stem from mutations in the prion protein (PrP) gene, producing abnormal prion isoforms.
  • Fatal familial insomnia (FFI) is a rare, inherited prion disease characterized by progressive sleep disorders, linked to a specific mutation at codon 178.

Observation:

  • Two male patients from the same family presented with severe sleep disturbances, including agitation, fragmented sleep, snoring, and daytime sleepiness.
  • Clinical course was rapid, with patient demise within months of symptom onset.
  • Sleep studies revealed disrupted sleep cycles, reduced sleep spindles, and K-complexes, alongside tachycardia and apneic pauses.

Findings:

  • Molecular analysis confirmed the D178N-129M genotype in both patients.
  • Neuropathological examination showed significant abnormalities in the thalamus (gliosis, neuronal loss) and inferior olive (neuronal loss).

Implications:

  • Polysomnography is crucial for diagnosing FFI, with thalamic and inferior olive alterations serving as key neuropathological markers.
  • Molecular diagnostics enable precise FFI diagnosis, though variability in phenotype and pathogenesis remains under investigation.

Related Concept Videos

Narcolepsy01:07

Narcolepsy

Narcolepsy is a chronic sleep disorder characterized by pervasive, uncontrolled sleepiness and other sleep disturbances. One of its hallmark symptoms is an abrupt transition to REM sleep upon falling asleep, which causes symptoms typically associated with this phase to occur unexpectedly during wakefulness. These include the following symptoms, which typically last from a minute or two to half an hour.
Sleep-Wake Cycles01:24

Sleep-Wake Cycles

Sleep is an essential physiological process vital to maintaining overall well-being. The reticular activating system (RAS), a network of neurons in the brainstem, regulates wakefulness and sleep. While it may seem passive, sleep consists of distinct cycles, each with its unique characteristics and functions. Two key sleep phases are non-rapid eye movement (NREM) and  rapid eye movement (REM).
NREM Sleep
NREM sleep comprises four progressive stages that seamlessly merge:
Insomnia01:27

Insomnia

Insomnia is a prevalent sleep disorder characterized by difficulty falling asleep, frequent awakenings during the night, and waking up too early without being able to return to sleep. People with insomnia often experience these disruptions at least three nights a week for at least one month. Chronic insomnia, which lasts for at least three months, can lead to increased anxiety, which in turn can worsen sleep difficulties, creating a cycle of sleeplessness and stress.
Multiple factors contribute...
Management of Insomnia01:19

Management of Insomnia

The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
CNS Depressants: Barbiturates and Benzodiazepines01:14

CNS Depressants: Barbiturates and Benzodiazepines

CNS depressants include drugs from the category of barbiturates and benzodiazepines. They are valuable medications for managing anxiety disorders and insomnia. Barbiturates, once used to induce and maintain sleep, have been replaced mainly by benzodiazepines due to barbiturate's toxicity, tolerance, and overdose risks. They interact with GABAA receptors, leading to sedation at low doses and potentially coma and death at higher doses. Phenobarbital, a long-acting barbiturate, possesses...